-
Tytuł:
-
Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement.
-
Autorzy:
-
Owens DK; Veterans Affairs Palo Alto Health Care System, Palo Alto, California.; Stanford University, Stanford, California.
Davidson KW; Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York.
Krist AH; Fairfax Family Practice Residency, Fairfax, Virginia.; Virginia Commonwealth University, Richmond.
Barry MJ; Harvard Medical School, Boston, Massachusetts.
Cabana M; University of California, San Francisco.
Caughey AB; Oregon Health & Science University, Portland.
Doubeni CA; Mayo Clinic, Rochester, Minnesota.
Epling JW Jr; Virginia Tech Carilion School of Medicine, Roanoke.
Kubik M; Temple University, Philadelphia, Pennsylvania.
Landefeld CS; University of Alabama at Birmingham.
Mangione CM; University of California, Los Angeles.
Pbert L; University of Massachusetts Medical School, Worcester.
Silverstein M; Boston University, Boston, Massachusetts.
Simon MA; Northwestern University, Evanston, Illinois.
Tseng CW; University of Hawaii, Honolulu.; Pacific Health Research and Education Institute, Honolulu, Hawaii.
Wong JB; Tufts University School of Medicine, Boston, Massachusetts.
-
Corporate Authors:
-
US Preventive Services Task Force
-
Źródło:
-
JAMA [JAMA] 2020 Feb 25; Vol. 323 (8), pp. 757-763.
-
Typ publikacji:
-
Journal Article; Practice Guideline; Research Support, U.S. Gov't, P.H.S.
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Chicago : American Medical Association, 1960-
-
MeSH Terms:
-
Mass Screening*/adverse effects
Cognitive Dysfunction/*diagnosis
Dementia/*diagnosis
Aged ; Cognitive Dysfunction/therapy ; Dementia/therapy ; Early Diagnosis ; Humans ; Independent Living ; Neuropsychological Tests ; Sensitivity and Specificity
-
Entry Date(s):
-
Date Created: 20200226 Date Completed: 20200311 Latest Revision: 20200311
-
Update Code:
-
20240105
-
DOI:
-
10.1001/jama.2020.0435
-
PMID:
-
32096858
-
Importance: Dementia (also known as major neurocognitive disorder) is defined by a significant decline in 1 or more cognitive domains that interferes with a person's independence in daily activities. Dementia affects an estimated 2.4 to 5.5 million individuals in the United States, and its prevalence increases with age.
Objective: To update its 2014 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for cognitive impairment, including mild cognitive impairment and mild to moderate dementia, in community-dwelling adults, including those 65 years or older residing in independent living facilities.
Population: This recommendation applies to community-dwelling older adults 65 years or older, without recognized signs or symptoms of cognitive impairment.
Evidence Assessment: The USPSTF concludes that the evidence is lacking, and the balance of benefits and harms of screening for cognitive impairment cannot be determined.
Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults. (I statement).
Comment in: JAMA Intern Med. 2020 Apr 1;180(4):483-484. (PMID: 32096825)
Comment in: JAMA. 2020 Feb 25;323(8):722-724. (PMID: 32096831)
Summary for patients in:JAMA. 2020 Feb 25;323(8):800. (PMID: 32096853)
Comment in: Ann Intern Med. 2020 Jul 21;173(2):JC2. (PMID: 32687759)